1. Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses
- Author
-
Nadereh, Naderi and Mahsa, Rahimzadeh
- Subjects
Adult ,Male ,ESR, erythrocyte sedimentation rate ,COVID-19, Coronavirus disease 2019 ,ILD, interstitial lung diseases ,CK, creatin kinase ,SARS-CoV-2 ,KL-6 ,Mucin-1 ,COVID-19 ,macromolecular substances ,Middle Aged ,Prognosis ,Severity of Illness Index ,Article ,KL-6, Krebs von den Lungen-6 ,IL, interleukin ,Virology ,CRP, C-reactive protein ,Humans ,Female ,Biomarkers ,NLR, neutrophil to lymphocyte ratio ,Aged - Abstract
Background Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells, and has been proposed as a marker of COVID-19 and the severity of the disease. Here, we performed a meta-analysis to determine whether KL-6 could be used as a prognostic factor for severe COVID-19. Methods PubMed, Cochrane and Google Scholar were searched until April 20, 2021, and 7 studies were included. KL-6 was considered as the outcome and pooled in meta-analyses. Results All included studies compared KL-6 in severe and non-severe patients. Serum KL-6 was higher in severe COVID-19 patients compared to non-severe (n = 6; SMD = 1.25; 95% CI: 0.99–1.5; P
- Published
- 2022